In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial.
Open Access
- 15 January 1996
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 97 (2) , 515-521
- https://doi.org/10.1172/jci118443
Abstract
Adoptive immunotherapy with tumor-infiltrating lymphocytes (TIL) and IL-2 appears to produce dramatic regressions in patients with metastatic melanoma and renal cancer. However, the in vivo mechanism of TIL function is not known. We conducted an UCLA Human Subject Protection Committee, Recombinant DNA Advisory Committee, and FDA-approved clinical trial using genetically-marked TIL to test the hypothesis that these cells have unique, tumor-specific in vivo trafficking patterns. TIL and PBL (as a control effector cell population) were isolated and expanded in parallel in vitro in IL-2-containing medium for 4-6 wk. During the expansion, TIL and PBL were separately transduced with the amphotropic retroviral vectors LNL6 and G1Na. Transduced TIL and PBL were coinfused into patients and their respective numbers measured in tumor, peripheral blood, and normal tissues; integrated provirus could be quantitated and distinguished by DNA PCR. Nine patients were treated (six melanoma, three renal) and received between 4.5 x 10(8) and 1.24 x 10(10) total cells. Both "marked" TIL and PBL could be detected circulating in the peripheral blood, in some patients for up to 99 d after infusion. Marked TIL and/or PBL could be detected in tumor biopsies in six of nine patients as early as day 6 and as late as day 99 after infusion. No convincing pattern of preferential trafficking of TIL vs. PBL to tumor was noted. Moreover, concurrent biopsies of muscle, fat, and skin demonstrated the presence of TIL/PBL in comparable or greater numbers than in tumor in five patients. The results of this double gene marking trial provide interesting insights into the life span and trafficking of adoptively transferred lymphocytes, but do not support the hypothesis that TIL specifically traffic to tumor deposits.Keywords
This publication has 36 references indexed in Scilit:
- Patterns of Cytokine Release of Unselected and CD8+ Selected Renal Cell Carcinoma Tumor-Infiltrating Lymphocytes (TIL): Evidence for Enhanced Specific Killing of Tumor Necrosis Factor-Secreting/IL-6 Nonsecreting TIL in Vitro and Correlation with Complete Response in VivoClinical Immunology and Immunopathology, 1994
- Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes.The Journal of Experimental Medicine, 1991
- TUMOUR-INFILTRATING LYMPHOCYTES AND INTERLEUKIN-2 IN TREATMENT OF ADVANCED CANCERThe Lancet, 1989
- Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic MelanomaNew England Journal of Medicine, 1988
- A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating LymphocytesScience, 1986
- Immunology of Tumor Infiltrating LymphocytesAnnals of Surgery, 1985
- Suppressor cell activity of lymphocytes infiltrating human lung and breast tumoursInternational Journal of Cancer, 1979
- Cytological and functional analysis of inflammatory infiltrates in human malignant tumors II. Functional investigations of the infiltrating inflammatory cellsEuropean Journal of Immunology, 1978
- Human tumour—lymphocyte interaction in vitro. V. Comparison of the reactivity of tumour‐infiltrating, blood and lymph‐node lymphocytes with autologous tumour cellsInternational Journal of Cancer, 1977
- Natural cytotoxicity in man: activity of lymph node and tumor‐infiltrating lymphocytesEuropean Journal of Immunology, 1977